{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:35:51Z","timestamp":1783467351154,"version":"3.55.0"},"reference-count":61,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Since immunoprophylaxis failure can occur if maternal serum hepatitis B virus (HBV) DNA levels are &gt;200,000\u00a0IU\/ml, tenofovir disoproxil fumarate (TDF) therapy has been investigated for preventing mother to child transmission (PMTCT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A literature search for maternal TDF therapy for PMTCT between 1\/1\/2015 and 7\/1\/21 on PUBMED, EMBASE, Cochrane, CNKI, and Wanfang databases was performed. Data from RCTs in English or Chinese were extracted and reviewed. The outcomes of interest included the efficacy and safety of TDF versus placebo for PMTCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 11 RCTs identified from the databases, the risk-of-bias was low. All studies demonstrated that maternal TDF therapy initiated from the second or third trimester for highly viremic chronic hepatitis B mothers is highly effective and safe in the PMTCT of HBV, except one RCT performed in Thailand which showed no therapeutic advantage on TDF treatment versus placebo for PMTCT (0% vs 3% transmission). Recent emerging data suggest that maternal TDF therapy initiated at the 2nd or early 3rd trimester in mothers with HBV DNA &gt;200,000\u00a0IU\/ml achieved viremic control before delivery. In the 4-year long follow-up study for maternal TDF therapy, there were no impacts on infants\u2019 physical growth, psychological or mental development, and bone mineral density after fetal exposure to TDF. In the light of updated efficacy and safety data from RCTs, an algorithm was proposed. The approaches in resource-limit areas were discussed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TDF is safe for both mothers and infants as the preferred therapy for PMTCT in highly viremic mothers. TDF should be initiated at the second or early third trimester in the combination of the appropriate infants\u2019 immunoprophylaxis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13596535221076640","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T06:43:10Z","timestamp":1650868990000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["The role of tenofovir disoproxil fumarate for preventing vertical transmission of hepatitis B"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3723-6688","authenticated-orcid":false,"given":"Calvin Q","family":"Pan","sequence":"first","affiliation":[{"name":"Beijing Ditan Hospital, Capital Medical University, Beijing, China"},{"name":"NYU Langone Health, NYU Grossman School of Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,4,25]]},"reference":[{"key":"bibr1-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30056-6"},{"key":"bibr2-13596535221076640","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.2.36"},{"key":"bibr3-13596535221076640","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2481"},{"key":"bibr4-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28156"},{"key":"bibr5-13596535221076640","unstructured":"WHO. Prevention of Mother-to-Child Transmission of Hepatitis B Virus: Guidelines on Antiviral Prophylaxis in Pregnancy. Geneva, Switzerland: WHO."},{"key":"bibr6-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.10.041"},{"key":"bibr7-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14577"},{"key":"bibr8-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-017-9825-y"},{"key":"bibr9-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01492.x"},{"key":"bibr10-13596535221076640","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2009.tb02524.x"},{"key":"bibr11-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-12-131"},{"key":"bibr12-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-014-0340-4"},{"key":"bibr13-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2008.01056.x"},{"key":"bibr14-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.02.032"},{"key":"bibr15-13596535221076640","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0168-8278(00)80758-8","volume":"32","author":"van Nunen AB","year":"2000","journal-title":"J Hepatol"},{"key":"bibr16-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2003.00440.x"},{"key":"bibr17-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.01.019"},{"key":"bibr18-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-012-2187-3"},{"key":"bibr19-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27034"},{"key":"bibr20-13596535221076640","volume-title":"Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B","author":"WHO","year":"2015"},{"key":"bibr21-13596535221076640","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i8.2504"},{"key":"bibr22-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"bibr23-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1939"},{"key":"bibr24-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10235-1"},{"key":"bibr25-13596535221076640","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/apt.16043","volume":"52","author":"Ding Y","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"bibr26-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33833-w"},{"key":"bibr27-13596535221076640","first-page":"378","volume":"28","author":"Liu M","year":"2017","journal-title":"Chin J Woman Child Health Res"},{"key":"bibr28-13596535221076640","first-page":"1094","volume":"43","author":"Chen G","year":"2019","journal-title":"Heilongjiang Med J"},{"key":"bibr29-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27837"},{"key":"bibr30-13596535221076640","first-page":"331","volume":"24","author":"Huang YQ","year":"2021","journal-title":"J Prac Hepatol"},{"key":"bibr31-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708131"},{"key":"bibr32-13596535221076640","first-page":"66","volume":"24","author":"Liu JJ","year":"2019","journal-title":"Chin Hepatol"},{"key":"bibr33-13596535221076640","first-page":"836","volume":"22","author":"Ma LY","year":"2019","journal-title":"J Prac Hepatol"},{"key":"bibr34-13596535221076640","first-page":"485","volume":"13","author":"Mao CJ","year":"2019","journal-title":"Chin J Exp Clin Infect Dis (Electronic Edition)"},{"key":"bibr35-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1508660"},{"key":"bibr36-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02025-1"},{"key":"bibr37-13596535221076640","first-page":"159","volume":"15","author":"Pan CQ","year":"2008","journal-title":"Curr Hepat B Rep"},{"key":"bibr38-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30056-6"},{"key":"bibr39-13596535221076640","volume-title":"Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission","author":"Pan CQ","year":"2018"},{"key":"bibr40-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1609991"},{"key":"bibr41-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322719"},{"key":"bibr42-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu798"},{"key":"bibr43-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30586-7"},{"key":"bibr44-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.06.036"},{"key":"bibr45-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28589"},{"key":"bibr46-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30593-4"},{"key":"bibr47-13596535221076640","first-page":"73","volume":"57","author":"Chen WJ","year":"2017","journal-title":"Shandong Med J"},{"key":"bibr48-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26011"},{"key":"bibr49-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15064"},{"key":"bibr50-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15382"},{"key":"bibr51-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251552"},{"key":"bibr52-13596535221076640","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S228982"},{"key":"bibr53-13596535221076640","unstructured":"APR. Interim Report Issued in May, 2021 for Data From 1 January 1989 Through 31 January 2021. (Accessed November 25, 2021.) Available from http:\/\/www.apregistry.com\/InterimReport.aspx"},{"key":"bibr54-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1016\/j.clp.2008.03.003"},{"key":"bibr55-13596535221076640","first-page":"216","volume":"7","author":"Aggarwal R","year":"1994","journal-title":"Natl Med J India"},{"key":"bibr56-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00120-7"},{"key":"bibr57-13596535221076640","volume-title":"Progress Report","author":"GAVI"},{"key":"bibr58-13596535221076640","first-page":"23","author":"Segeral O","year":"2021","journal-title":"EASL Int Liver Congress"},{"key":"bibr59-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy982"},{"key":"bibr60-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.01.021"},{"key":"bibr61-13596535221076640","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.039"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535221076640","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13596535221076640","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535221076640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:53:05Z","timestamp":1777380785000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13596535221076640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1177\/13596535221076640"],"URL":"https:\/\/doi.org\/10.1177\/13596535221076640","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]},"article-number":"13596535221076640"}}